Cargando…
Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry
BACKGROUND: Cannabidiol (CBD) is a major chemical compound present in Cannabis sativa. CBD is a nonpsychotomimetic substance, and it is considered one of the most promising candidates for the treatment of psychiatric disorders. OBJECTIVE: The aim of this review is to illustrate the state of art abou...
Autores principales: | Calapai, Gioacchino, Mannucci, Carmen, Chinou, Ioanna, Cardia, Luigi, Calapai, Fabrizio, Sorbara, Emanuela Elisa, Firenzuoli, Bernardo, Ricca, Valdo, Gensini, Gian Franco, Firenzuoli, Fabio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735178/ https://www.ncbi.nlm.nih.gov/pubmed/31558911 http://dx.doi.org/10.1155/2019/2509129 |
Ejemplares similares
-
Pharmacovigilance on cannabidiol as an antiepileptic agent
por: Ammendolia, Ilaria, et al.
Publicado: (2023) -
Effects of Cannabidiol on Locomotor Activity
por: Calapai, Fabrizio, et al.
Publicado: (2022) -
Cannabinoids, Blood–Brain Barrier, and Brain Disposition
por: Calapai, Fabrizio, et al.
Publicado: (2020) -
Clinical use of omega-3 fatty acids in migraine: A narrative review
por: Cardia, Luigi, et al.
Publicado: (2020) -
Preclinical and Clinical Pharmacology of Hydrocodone for Chronic Pain: A Mini Review
por: Cardia, Luigi, et al.
Publicado: (2018)